We studied the practice patterns regarding intravenous (i.v.) ondansetron in children receiving stem cell transplants ( 
While the introduction of the selective serotonin receptor antagonists has greatly enhanced the control of acute chemotherapy-induced nausea and vomiting, the drug acquisition cost of these agents is considerably higher than conventional antiemetic therapy. [1] [2] [3] [4] There is general consensus about the need to balance clinical efficacy and cost. [5] [6] [7] However, identifying and understanding the individual contributing factors to all components of costs and the actual steps required to accomplish that balance are less well defined.
The 5-hydroxytryptamine (5-HT 3 ) receptor antagonists have been extensively tested in clinical trials, initially in general oncology and more recently, in stem cell transplantation (SCT) and have been shown to be more effective than conventional agents in emesis control following moderately and highly emetogenic chemotherapy in children and adults. [8] [9] [10] These agents have demonstrated similar clinical efficacy when administered parenterally as either once daily or divided dosing (ie the first 24 h after initiation of treatment) in the acute phase of chemotherapy-related nausea and vomiting. 11, 12 Recent studies have shown that the oral formulation of these agents is as effective as the parenteral route both for moderate and highly emetogenic chemotherapy. [13] [14] [15] [16] [17] [18] [19] Obtaining effective control of emesis in the SCT patient can be challenging because of the highly emetogenic nature of the conditioning regimens, often administered over several days, the added emetogenicity of radiation, and the combined acute and delayed patterns of emesis experienced. Nevertheless, several studies in adults and children have demonstrated that the 5-HT 3 receptor antagonists are effective in controlling conditioning-related emesis, both during high dose chemotherapy 8, 14, 15 and total body irradiation. 10, [20] [21] [22] [23] [24] [25] Recent studies in SCT demonstrate that once daily dosing is equivalent to divided dosing and that equivalence is demonstrated with either the parenteral or oral formulation, mirroring findings in the general oncology population. 8, 12, 24, 25 While the efficacy of the 5-HT 3 receptor antagonists is superior in the acute phase of chemotherapy or radiotherapy-induced nausea and vomiting, this efficacy diminishes dramatically in the delayed phase (ie Ͼ24 h). This delayed phase of therapy-related emesis is experienced more often in chemotherapy regimens containing platinumcontaining agents, high-dose cyclophosphamide or doxorubicin. 26, 27 Therefore, the adoption of alternative therapy for delayed nausea and vomiting has been useful. [28] [29] [30] Faced with a steadily rising annual budget, our institution's Pharmacy and Therapeutics Committee directed each clinical program to evaluate utilization patterns and maximize the cost effectiveness of those drugs with the highest level of annual expenditure. Antiemetics and colony-stimulating factors were two drug categories identified by our program for an initial evaluation. In response to requests to be more cost conscious, our clinical program formally studied the practice patterns regarding parenterally administered (i.v.) ondansetron (Zofran; Cerenex, Research Triangle Park, NC, USA), the 5-HT 3 antagonist on formulary, in children receiving SCT at the Children's Hospital, Boston to identify areas for potential cost efficiencies.
We have developed a paradigm for analyzing drug costs in a health care environment which is increasingly costconscious. Specifically, this paradigm characterizes the cost relationships that exist between clinician prescribing practices, pharmacy stocking and distribution practices, and manufacturer's decisions regarding drug production, available dosing units, and pricing structure (Figure 1 ). In this paper we report our findings regarding the use of antiemetics in the SCT population; the results of the colony-stimulating factors evaluation utilizing this model are reported elsewhere. 31 The goal of this analysis was to identify possible cost-containment strategies in the use of highly potent, yet expensive, 5-HT 3 antagonist antiemetics while maintaining clinical efficacy and access to these clinically important drugs.
Methods

Patient sample
The sample included 36 patients who received 41 transplants and parenterally administered ondansetron. This sample was derived from the total of 55 transplants in 50 patients performed in FY95. Patients were excluded from this analysis if complete cost information was not available or if they received a combination of parenteral and oral ondansetron. In addition, one patient was excluded from the modeling as a weight outlier (eg Ͼtwice the weight of the next heaviest patient). Information from the hospital's pharmacy records and financial records was linked to each SCT hospitalization via unique identifiers including name, medical record number, date of birth, and dates of hospitalization. The dates of intravenous ondansetron use, daily dosage, dosing schedule, and the total number of doses dispensed per patient for each SCT hospitalization were collected. 
Costs
Pharmacy provided all information on both the material cost and the cost of dispensing (preparing) one dose of ondansetron, depending on dosage form (ie dose fee code). For this study, the total direct cost for one dose of ondansetron is the sum of material and preparation cost, exclusive of drug administration costs (eg nursing labor or supplies) or institutional overhead. Material costs are based on the institutionally negotiated discounts of the wholesale acquisition cost (WAC), available to health care facilities via group purchasing agreements. The WAC is approximately 80% of the average wholesale price (AWP). When combined with institutional discounts from group purchasing agreements, the resultant cost is approximately 75-80% of the AWP. Material costs in our institution were $165/40 mg for the parenteral formulation, $112/40 mg for the oral solution, and $8/4 mg for the oral tablet. The preparation cost is the fee associated with dispensing the drug and is dependent upon the formulation (eg parenteral, oral tablets or solution). This fee, set by the Pharmacy Department was $1.51 for a tablet, $7.53 for the oral solution, and $20.07 for the i.v. preparation. The cost information was not inflation-adjusted to current year dollars and thus reflects 1995 dollars (95$).
In this model, we calculated the effects of dosing schedule, duration, and route of administration on drug costs using weight-based dosing (0.45 mg/kg/day) for the i.v. formulation. For the oral formulations (tablets and solution), we used the manufacturers' age-based recommendations. 32 These recommendations for oral administration are: 4 mg three times daily for children 4-11 years and 8 mg twice daily for children 12 years and older. Since no recommendations are available for children less than 4 years of age, the oral solution was modeled using weight-based dosing (0.45 mg/kg/day) on a three times daily divided dosing schedule. Information on cost of these oral forms of ondansetron, in addition to the various charges for preparing the different forms of the same drug, were obtained from our pharmacy. The duration was modeled for either 7 or 10 days based on an additional 24 h of anti-emetic coverage after completion of the preparative regimen typically of 6-9 days duration.
Results
Patient and treatment characteristics of the 41 SCT are depicted in Table 1 . Four hundred and ninety-eight days of i.v. ondansetron were administered, accounting for an annual expenditure of $49 083 (95$). Initial review of pharmacy's dispensing records of intravenous ondansetron revealed considerable variability with respect to dosing schedule and duration of treatment. Despite convincing data of the utility of a daily dosing regimen, ondansetron was administered on a daily basis in only eight (20%) of the transplants, on a divided schedule in 28 transplants (68%), and a combination of daily and divided dosing in the remaining five (12%). The median duration of treatment was 11 days (range, 1-48 days) at an average dose of 0.45 mg/kg/day, independent of dosing schedule. There-555 Table 1 Patient and treatment characteristics of study sample (n = 36) fore, the prescribing practices of clinicians became the focus of this analysis given the dramatic variability of use, and the implications of these decisions.
We first modeled cost variations related to frequency of i.v. ondansetron administration. The preparation costs were $20.07/day for the daily dose and three times more, or $60.21/day, for three times daily dosing. Therefore, an overall saving of 28% for the total population and 35% in the subset of patients who previously received only divided dosing would be achieved by switching to once daily dosing. The impact of this change would vary by patient weight, reflecting the different ratios of material to preparation costs ( Figure 2) .
Next, we examined cost variations related to duration of ondansetron administration. This model was designed to limit or cap the duration of proposed daily treatment at 24 h after completion of the SCT conditioning regimen given Bone Marrow Transplantation the published maximal efficacy of serotonin antagonists for acute phase regimen-related emesis. The median length of the conditioning regimen was 6 days (range, 6-9 days). A 10-day cap would result in additional savings of 28%, while a 7-day cap would translate to savings of 45% compared to daily i.v. dosing ( Figure 3) . Overall, the combined strategy of daily i.v. dosing for a fixed 7-day duration would result in up to 60% savings (estimated $29 680/year) over current practice. Finally, we evaluated cost variations related to route of ondansetron administration, parenteral vs oral. This model was based on growing evidence of the equivalence of the two routes in adults as previously cited. By shifting from an intravenous to oral route of administration, either solution or tablets, a cost saving (over current use) of 67% would be realized without a cap on drug duration (Figure 3) . The magnitude of these savings is a function of both decreases in material cost as well as a dramatic decrease in the preparative costs. Specifically, the preparative cost for tablets and the solution is significantly less than the i.v. formulation (92% and 63% less, respectively). If this approach was combined with a cap on the duration of treatment, the savings would be even greater.
Discussion
The highly selective 5-HT 3 receptor antagonists offer significant therapeutic advantages in the prevention of acute chemotherapy-or radiotherapy-induced nausea and vomiting in both general oncology and SCT populations. These advantages include superior emesis control, ease of administration, and a more favorable toxicity profile than conventional antiemetic therapy. Despite mounting evidence of their therapeutic benefit, the considerably higher material costs of these agents necessitate careful control of their use. Although drug costs in our institution and elsewhere account for a relatively small percentage of total SCTrelated cost (estimated 11%), they represent a significant portion of the variable costs and, therefore, warrant close scrutiny. The physical and psychological costs of poorly controlled nausea and vomiting can also be significant and should be taken into account when evaluating the balance between efficacy and costs. 33, 34 We demonstrated in this analysis that considerable cost savings can be achieved by standardizing dosing schedule and duration, the latter related to the length of the conditioning regimen. In addition, further savings could be achieved by switching from i.v. to oral formulations, based on published data in the SCT population. 21, 24, 25 These savings are achieved without changing practitioner-prescribing access to this important class of drugs. Other cost reduction strategies, such as decreased daily dosage or substitution with less expensive alternative agents, have been proposed, [35] [36] [37] [38] [39] but were not considered in our analysis. To realize projected cost savings, standardized guidelines addressing each of these variables (schedule of administration, duration of treatment and route), must be developed and implemented. The use of standardized guidelines for these agents has been shown in several studies to enhance cost control of their use. 5, [39] [40] [41] In addition, education of clinical staff, pharmacy, and families is necessary, including formal recommendations of alternate treatment strategies in case of poor antiemetic control. Post-implementation monitoring of emetic control and side-effects is also imperative to ensure no adverse clinical impact. These strategies are currently underway at our institution.
Even with the use of standardized guidelines, some individualization of treatment may be required. For example, using ondansetron solution, although more expensive than tablets, may be most appropriate for a younger child to ensure maximum patient tolerance. In addition, patients receiving highly emetogenic conditioning regimens should be targeted for the most aggressive anti-emetic therapy that may require use of multiple agents and/or sequential administration of these agents. In these instances, standardized guidelines must be balanced with formal clinical reevaluation.
Utilizing the model described in this study, we were able to identify potential areas of cost savings, namely modification of the prescribing practices of clinicians. These modifications were based on published studies of equal clinical efficacy of various regimens. In a similar analysis of the use of colony-stimulating factors in the SCT population, we demonstrated cost efficiencies by altering stocking and distributing practices of the pharmacy and had implications for the manufacturer related to vial sizes needed for the pediatric population. 31 In sum, these analyses highlight the need to identify and understand all of the factors contributing to drug costs when making decisions about appropriate access to 'expensive' drugs to maintain the balance between optimal efficacy and reasonable costs.
